HSK42360

· Haisco Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HSK42360, covering 2024-08-05 to 2025-09-08. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation [Phase 1]